Abstract
AbstractThe COVID-19 pandemic has continued to exert enormous pressure on public health policies and systems, with far-reaching implications. The race for vaccines has raised important intellectual property rights issues. These are evident in the need to advance the public interest and in the obligation of governments to address the challenge of access to vaccines, especially in sub-Saharan countries like Nigeria with relatively underdeveloped healthcare and innovation ecosystems. While the Nigerian Patents and Designs Act (PDA) establishes a compulsory licence regime that affords access to patented drugs, existing public healthcare is severely challenged in providing access to new medicines. This article examines the framework for patent protection of pharmaceuticals designed to meet public health challenges, such as those presented by the pandemic. It recommends the implementation of a government use provision under the PDA, with a view to addressing the challenge of access to COVID-19 vaccines.
Publisher
Cambridge University Press (CUP)
Reference7 articles.
1. Public health, access to medicines and the role of patent system in Nigeria;Adewopo;Nigerian Institute of Advanced Legal Studies Journal of Intellectual Property,2011
2. Patent rights and essential medicines in developing countries: Is access compromised for innovation in Nigeria?;Kolawole;Journal of Medicine and Medical Sciences,2012
3. The History Of Vaccines And Immunization: Familiar Patterns, New Challenges
4. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016
5. The TRIPS waiver is necessary, but it alone is not enough to solve equitable access to COVID-19 vaccines;Eccleston-Turner;American Society of International Law Newsletter,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献